- Home
- TRVI vs ATAI Comparison
TRVI vs ATAI Comparison
Compare TRVI & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRVI | ATAI |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TRVI | ATAI |
|---|---|---|
| Price | $10.15 | $4.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | ★ $20.38 | $13.86 |
| AVG Volume (30 Days) | 1.3M | ★ 3.9M |
| Earning Date | 03-17-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,018,000.00 |
| Revenue This Year | N/A | $962.66 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 811.78 |
| 52 Week Low | $3.73 | $1.15 |
| 52 Week High | $14.39 | $6.75 |
Technical Indicators
Market Signals| Indicator | TRVI | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 34.14 | 57.09 |
| Support Level | $10.17 | $3.50 |
| Resistance Level | $11.15 | $3.85 |
| Average True Range (ATR) | 0.73 | 0.22 |
| MACD | -0.13 | 0.04 |
| Stochastic Oscillator | 3.52 | 99.34 |
Price Performance
Historical ComparisonAbout TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.